Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa
MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events Data from the Phase ...